Pharma’s Words Of Wisdom For Prospective Biotech Partners
Low Prices Not Changed The Foundations Of Dealmaking
Stay patient and concentrate on building trust rather than the bank balance was one of the key pieces of advice offered by business development heads at Regeneron and Eli Lilly to start-ups attending the recent BIO-Europe meeting.
You may also be interested in...
Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.
The Belgian group was stunned by an FDA rejection in May for its dual IL-17A and IL-17F inhibitor and although the refiling is complete, UCB may still have to wait six months to get Bimzelx into the all-important US psoriasis market.